Therapy monitoring and tumor surveillance control in prostate cancer are mainly based on quantification of serum levels of prostate-specific antigen (PSA); however, due to a high rate of false positive results, the benefits of the PSA as a serum marker are the subject of controversial discussion [11]. This evidence concerns the gene KLK3 and Familial prostate cancer.